Logo image of PTE

POLARITYTE INC (PTE) Stock Fundamental Analysis

NASDAQ:PTE - Nasdaq - US7310942070 - Common Stock - Currency: USD

0.241  0 (-0.82%)

After market: 0.2249 -0.02 (-6.68%)

Fundamental Rating

3

Taking everything into account, PTE scores 3 out of 10 in our fundamental rating. PTE was compared to 559 industry peers in the Biotechnology industry. While PTE seems to be doing ok healthwise, there are quite some concerns on its profitability. PTE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PTE had negative earnings in the past year.
PTE had a negative operating cash flow in the past year.
In the past 5 years PTE always reported negative net income.
In the past 5 years PTE always reported negative operating cash flow.
PTE Yearly Net Income VS EBIT VS OCF VS FCFPTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

PTE has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTE Yearly ROA, ROE, ROICPTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K -2K -2.5K

1.3 Margins

PTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTE Yearly Profit, Operating, Gross MarginsPTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

PTE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTE has been increased compared to 1 year ago.
Compared to 1 year ago, PTE has an improved debt to assets ratio.
PTE Yearly Shares OutstandingPTE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
PTE Yearly Total Debt VS Total AssetsPTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -43.73, we must say that PTE is in the distress zone and has some risk of bankruptcy.
PTE has a worse Altman-Z score (-43.73) than 91.49% of its industry peers.
There is no outstanding debt for PTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -43.73
ROIC/WACCN/A
WACC9.96%
PTE Yearly LT Debt VS Equity VS FCFPTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

A Current Ratio of 4.11 indicates that PTE has no problem at all paying its short term obligations.
PTE's Current ratio of 4.11 is in line compared to the rest of the industry. PTE outperforms 43.02% of its industry peers.
PTE has a Quick Ratio of 4.11. This indicates that PTE is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.11, PTE perfoms like the industry average, outperforming 43.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.11
Quick Ratio 4.11
PTE Yearly Current Assets VS Current LiabilitesPTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.44% over the past year.
The Revenue for PTE has decreased by -98.66% in the past year. This is quite bad
The Revenue for PTE have been decreasing by -47.73% on average. This is quite bad
EPS 1Y (TTM)61.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.22%
Revenue 1Y (TTM)-98.66%
Revenue growth 3Y-47.73%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 28.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 176.69% on average over the next years. This is a very strong growth
EPS Next Y48.01%
EPS Next 2Y33.03%
EPS Next 3Y35.36%
EPS Next 5Y28.11%
Revenue Next Year-100%
Revenue Next 2Y179.39%
Revenue Next 3Y299.65%
Revenue Next 5Y176.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PTE Yearly Revenue VS EstimatesPTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 100M 200M 300M
PTE Yearly EPS VS EstimatesPTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PTE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTE Price Earnings VS Forward Price EarningsPTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTE Per share dataPTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PTE's earnings are expected to grow with 35.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.03%
EPS Next 3Y35.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POLARITYTE INC

NASDAQ:PTE (6/15/2023, 8:20:22 PM)

After market: 0.2249 -0.02 (-6.68%)

0.241

0 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2023-05-12/amc
Earnings (Next)08-09 2023-08-09
Inst Owners0%
Inst Owner Change-16.67%
Ins Owners114.99%
Ins Owner Change0%
Market Cap1.78M
Analysts80
Price Target0.82 (240.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.81%
Min EPS beat(2)16.77%
Max EPS beat(2)92.84%
EPS beat(4)3
Avg EPS beat(4)42.05%
Min EPS beat(4)-2.97%
Max EPS beat(4)92.84%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)43.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.35
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-2.41
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-2.93
FCFYN/A
OCF(TTM)-2.93
OCFYN/A
SpS0.01
BVpS1.68
TBVpS1.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.11
Quick Ratio 4.11
Altman-Z -43.73
F-Score2
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)15.96%
Cap/Depr(5y)150.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.22%
EPS Next Y48.01%
EPS Next 2Y33.03%
EPS Next 3Y35.36%
EPS Next 5Y28.11%
Revenue 1Y (TTM)-98.66%
Revenue growth 3Y-47.73%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y179.39%
Revenue Next 3Y299.65%
Revenue Next 5Y176.69%
EBIT growth 1Y34.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.09%
OCF growth 3YN/A
OCF growth 5YN/A